![]() |
Volumn 12, Issue 3, 2001, Pages 308-311
|
The regulation of biologic products derived from bioengineered plants
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIBODY;
BIOLOGICAL PRODUCT;
IMMUNOGLOBULIN E;
IMMUNOGLOBULIN G;
VACCINE;
BIOENGINEERING;
CONTRACT;
COST EFFECTIVENESS ANALYSIS;
DRUG MANUFACTURE;
DRUG STRUCTURE;
GENETIC TRANSFECTION;
GOOD MANUFACTURING PRACTICE;
HUMAN;
INFECTION;
NONHUMAN;
PLANT;
PLANT SEED;
PRIORITY JOURNAL;
PROPHYLAXIS;
REVIEW;
RISK;
TECHNOLOGY;
TOBACCO MOSAIC VIRUS;
ANIMALS;
BIOLOGICAL PRODUCTS;
BIOTECHNOLOGY;
DNA, RECOMBINANT;
GENETIC ENGINEERING;
GLYCOPROTEINS;
HUMANS;
LEGISLATION;
PLANTS, GENETICALLY MODIFIED;
SEEDS;
UNITED STATES;
UNITED STATES DEPARTMENT OF AGRICULTURE;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
EID: 0035369779
PISSN: 09581669
EISSN: None
Source Type: Journal
DOI: 10.1016/S0958-1669(00)00217-2 Document Type: Review |
Times cited : (24)
|
References (16)
|